GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » Net Change in Cash

Grand Pharmaceutical Group (HKSE:00512) Net Change in Cash : HK$-104 Mil (TTM As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Grand Pharmaceutical Group's Net Change in Cash for the six months ended in Dec. 2023 was HK$646 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-104 Mil.

Grand Pharmaceutical Group Net Change in Cash Historical Data

The historical data trend for Grand Pharmaceutical Group's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group Net Change in Cash Chart

Grand Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 147.03 777.43 -83.84 -308.85 -104.31

Grand Pharmaceutical Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -584.66 -717.98 409.13 -750.40 646.10

Grand Pharmaceutical Group Net Change in Cash Calculation

Grand Pharmaceutical Group's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=2424.895+-515.747+-1889.399+-124.055
=-104

Grand Pharmaceutical Group's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=1675.753+59.79+-1228.762+139.315
=646

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-104 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Pharmaceutical Group Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Grand Pharmaceutical Group (HKSE:00512) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » Net Change in Cash
Comparable Companies
HKSE:00867 HKSE:03933 HKSE:02096 HKSE:02005 HKSE:00570 HKSE:06600 HKSE:02186 HKSE:06185 HKSE:01558 HKSE:03613 XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
MX6A:Germany
Address
99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG
Website
http://www.chinagrandpharm.com
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.
Executives
Shang Hai Yuan Da Chan Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Hu Kaijun 2201 Interest of corporation controlled by you
East Ocean Capital (hong Kong) Company Limited 2101 Beneficial owner
Lion River I N.v. 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd. 2201 Interest of corporation controlled by you
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Citic Group Corporation 2201 Interest of corporation controlled by you
Citic Limited 2201 Interest of corporation controlled by you
China Citic Bank Corporation Limited 2201 Interest of corporation controlled by you
Cncb (hong Kong) Investment Limited 2106 Person having a security interest in shares
Grand (hongkong) International Investments Holdings Limited
Chau Tung
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si
Outwit Investments Limited

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines